We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Ventilator Aspiration With PneuX (PneuX vs Standard Care Feasibility RCT) (VAP-X)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05410106
Recruitment Status : Recruiting
First Posted : June 8, 2022
Last Update Posted : January 5, 2023
Cardiff University
Information provided by (Responsible Party):
Cardiff and Vale University Health Board

Brief Summary:
This is a single centre, open-label, feasibility randomised controlled trial. The study aims to assess the feasibility of conducting an RCT to compare the PneuX ETT with standard care in hospitalised patients requiring mechanical ventilation. The patient population for this study are those who are experiencing critical illness requiring intubation and ventilatory support. Patients will be randomised in equal proportions into one of 2 arms: to be intubated using a Venner PneuX Endotracheal Tube (ETT) or using the standard tube. For this feasibility study, a total of 50 patients will be randomised into two groups (25 in each). All patients will be recruited at a single site (University Hospital of Wales, part of Cardiff & Vale UHB). The study will investigate several feasibility measures including recruitment, delivery of the intervention (including device-related adverse events), acceptability and adherence to the intervention and sampling, use of Peptest to measure microaspiration events, rate of pepsin positive samples, rate of tracheobronchial colonisation, volume of sub-glottic aspirate, rate of VAP, length of ICU and hospital stay, demonstrate the validity of study documentation and provide preliminary data for 50 patients. The data will inform the pilot and main phase of the study.

Condition or disease Intervention/treatment Phase
Ventilator Associated Pneumonia Aspiration Infections Ventilator Lung Device: PneuX Endotracheal Tube Device: Standard care (Taperguard, Covidien) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Feasibility, 2-arm, parallel, randomised controlled trial
Masking: Single (Participant)
Masking Description: Due to the nature of the interventional device it is not possible to blind the care providers or outcome assessors to the intervention group. The trial participants will be unconscious/sedated for the duration of the period that the PneuX device or standard ETT is in place and therefore will be unaware of their allocation. Samples sent to the laboratory for analysis will be anonymised using individual deidentified numbers for each participant.
Primary Purpose: Prevention
Official Title: A Single Centre, Open-label, Feasibility Randomised Controlled Trial to Evaluate Gastric Microaspiration in Critically Ill Patients Intubated Using the Venner PneuX System Compared to Standard of Care Using Pepsin Biomarker (VAP-X)
Actual Study Start Date : December 5, 2022
Estimated Primary Completion Date : July 1, 2023
Estimated Study Completion Date : July 1, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PneuX endotracheal tube
Patients will be intubated using the PneuX endotracheal tube system
Device: PneuX Endotracheal Tube
The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
Other Name: Venner PneuX System

Active Comparator: Standard care
Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).
Device: Standard care (Taperguard, Covidien)
Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.

Primary Outcome Measures :
  1. To assess if a recruitment rate of 50 patient annually is achievable and identify any barriers to recruitment [ Time Frame: Through study completion, an average of 1 year ]
    The recruitment rate will be assessed using the "screening and recruitment log" which will record the number of patients recruited each month and reasons for non-recruitment will be described

Secondary Outcome Measures :
  1. To assess the feasibility of delivering the study intervention [ Time Frame: Duration of study treatment (typically 4-7 days) ]
    Any issues experienced when using the study device at any point during the study will be recorded in the CRF, including device-related complications.

  2. Number of participants with a failed pepsin test [ Time Frame: Duration of study treatment (typically 4-7 days) ]
    Any issues such as failed sampling or failed testing will be recorded in case report form

  3. Number of participants with a positive pepsin tracheal aspirate sample using Peptest [ Time Frame: Duration of study treatment (typically 4-7 days) ]
    The proportion of tracheal aspirate samples which are positive for the presence of pepsin using the Peptest test

  4. Volume of sub-glottic aspirates [ Time Frame: Duration of study treatment (typically 4-7 days) ]
    The volume of the sub-glottic aspirates will be measured every 24 hours

  5. Rate of tracheobronchial colonization [ Time Frame: Duration of study treatment (typically 4-7 days) ]
    Tracheobronchial colonization (no. colony forming units/ml) present in sputum samples will be measured by culture on days 3 and 7

  6. Proportion of patients who require antibiotics [ Time Frame: 28 days ]
    The following will be assessed: antibiotic prescribed, indication for use, number of days administered

  7. Rate of Ventilator Associated Pneumonia (VAP) [ Time Frame: 28 days ]
    Number of patients with VAP diagnosis. Clinical Pulmonary Infection Score (CPIS) used to predict VAP. CPIS >6 will be used to define confirmation of VAP. Measured daily after 48 hours of intubation

  8. Time spent on the ventilator [ Time Frame: Duration of study treatment (typically 4-7 days) ]
    Days spent with mechanical ventilation in ICU (from time/date of intubation to time/date of extubation or 28 days)

  9. Number of days spent in ICU and hospital [ Time Frame: 28 days ]
    Length of stay in ICU and length of stay in hospital measured in days from ventilation

  10. Rate of in-hospital mortality [ Time Frame: 28 days ]
    Number of patients who die in hospital up to 28 days after entry into ICU

  11. Rate of compliance with measuring and documenting cuff pressure [ Time Frame: Duration of study treatment (typically 4-7 days) ]
    Documentation of cuff pressures in both arms of study. Cuff pressure in standard care will be measured every 12 hours. Assessment of intervention arm will have documentation that pressure has been maintained hourly either via the continual cuff pressure monitor or manually.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years old (no upper age)
  • Patient required endotracheal intubation
  • Expect to remain intubated for 24 hours post randomisation

Exclusion Criteria:

  • The person intubating the patient assesses that the patient has already aspirated.
  • GCS 7 or less on presentation to hospital
  • Patient is pregnant
  • Patient has tracheostomy
  • Patient has gastrectomy
  • Patients who have been intubated prior to arrival at hospital
  • Patients who are already endotracheally intubated and require a tube change.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05410106

Layout table for location contacts
Contact: Judith White 02921844771 judith.white3@wales.nhs.uk
Contact: Rhys Morris 0292144772 Rhys.Morris@wales.nhs.uk

Layout table for location information
United Kingdom
University Hospital of Wales Recruiting
Cardiff, United Kingdom, CF14 4XW
Contact: Jade Cole    029 21 843608    Jade.Cole@wales.nhs.uk   
Sponsors and Collaborators
Cardiff and Vale University Health Board
Cardiff University
Layout table for investigator information
Study Chair: Matthew Wise Cardiff and Vale University Health Board
Principal Investigator: Matthew Wise Cardiff and Vale University Health Board
Layout table for additonal information
Responsible Party: Cardiff and Vale University Health Board
ClinicalTrials.gov Identifier: NCT05410106    
Other Study ID Numbers: 21/NOV/8290
First Posted: June 8, 2022    Key Record Dates
Last Update Posted: January 5, 2023
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cardiff and Vale University Health Board:
Ventilator Associated Pneumonia
endotracheal tube
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Respiratory Tract Infections
Lung Diseases
Respiratory Tract Diseases
Healthcare-Associated Pneumonia
Cross Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes